Dexter Jie Yan

Dexter Jie Yan

Senior Reporter

Shanghai, China

Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in R&D and commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.

Latest from Dexter Jie Yan

Finotonlimab A China IO Latecomer But First In Country For 1L HNSCC

SinoCellTech's PD-1 inhibitor finotonlimab has become the first immuno-oncology drug to be approved in China for first-line head and neck squamous cell carcinoma regardless of PD-L1 expression.

Innogen’s Newly Approved GLP-1 Contender Girds For China Ozempic Battle

Innogen is hoping the approval of its once-weekly GLP-1 drug Diabegone will allow it to chip away at Ozempic’s dominance in the Chinese diabetes market.

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease

Plus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.

Chinese Vaccine Firms Forecast Plunging Profit

A combination of heightened competition, destocking at vaccination clinics and a slowing economy resulted in a disappointing year for major Chinese vaccine companies.

Degraders, ADCs, PDCs Shine In Latest China Funding Rounds

Degron and TargetRx’s targeted protein degrader programs helped the firms garner new venture capital backing, while VelaVigo and Conjustar were among the others bagging new funding for antibody- and peptide-drug conjugates.

Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku

Plus deals involving Simcere/AbbVie, Daiichi Sankyo/Glycotope, Telix/ImaginAb, Harbour/Kelun/Windward, Insilico/Menarini, Samsung Bioepis/Teva, HealZen/J&J, Zai Lab/Vertex, Zai Lab/MediLink and Primrose/Serum Institute of India.